trending Market Intelligence /marketintelligence/en/news-insights/trending/duV7DWoPPFUxLXw6oLpbfg2 content esgSubNav
In This List

Daiichi Sankyo, Nektar Therapeutics terminate breast cancer drug license deal

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Daiichi Sankyo, Nektar Therapeutics terminate breast cancer drug license deal

Nektar Therapeutics said it will pay Daiichi Sankyo Co. Ltd. a $12.5 million fee for the termination of a collaboration and license agreement for Onzeald, a drug intended to treat breast cancer.

The fee was paid to the Japanese company's European unit. Termination of the agreement with Daiichi Sankyo Europe GmbH will take effect Feb. 4, 2018, after which all rights and licenses granted to Daiichi will revert exclusively to Nektar.

The European Medicines Agency's Committee for Medicinal Products for Human Use refused to grant marketing authorization for Onzeald after Nektar requested a re-examination of the committee's negative opinion for the drug.

The payment will not have any impact on Nektar's 2017 earnings outlook.